Lancet. 2016; RADIANT-4; Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4) a randomised, placebo-controlled, phase 3

Telegram
ШµЩЃШ­Щ‡ Ш§ЫЊЩ†ШіШЄШ§ЪЇШ±Ш§Щ… ШЇЪ©ШЄШ± Ш№ШЁЫЊШЇЫЊ
پزشکان